Bacillus Calmette-Guerin Immunotherapy of Infiltrating Bladder Cancer
- 1 October 1984
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 132 (4) , 675-676
- https://doi.org/10.1016/s0022-5347(17)49818-1
Abstract
Oral administration of BCG was used to treat 10 patients with muscle invasive transitional cell carcinoma of the bladder. The treatment induced tumor regression in 7 patients (70%), including 1 who died without evidence of recurrent tumor. Skin test reactivity was correlated with response to treatment. Only 1 patient had marked skin test reactivity at the time of tumor recurrence. Patients with invasive bladder cancer may derive benefit from immunotherapy.This publication has 11 references indexed in Scilit:
- A Comparison of Treatment Methods for the Prophylaxis of Recurrent Superficial Bladder TumorsJournal of Urology, 1983
- Chemoimmune Prophylaxis of Superficial Bladder CancerJournal of Urology, 1983
- Bladder Cancer ImmunotherapyJournal of Urology, 1982
- Treatment of Residual, Non-infiltrating Bladder Cancer with Bacillus Calmette-guerinJournal of Urology, 1981
- Bladder cancerCurrent Problems in Surgery, 1981
- Bacillus Calmette-guerin Immunotherapy of Superficial Bladder CancerJournal of Urology, 1980
- Bladder cancer as seen in giant histologic sectionsCancer, 1977
- Intracavitary Bacillus Calmette-guerin in the Treatment of Superficial Bladder TumorsJournal of Urology, 1976
- Correlation Among Host Immunocompetence and Tumor Stage, Tumor Grade and Vascular Permeation in Transitional CarcinomaJournal of Urology, 1973
- The treatment of bladder carcinoma by local excision and fulgurationCancer, 1956